Cargando…

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

PURPOSE: Stereotactic body radiotherapy (SBRT) may have significant immunomodulatory effects that enhance tumor response to immune checkpoint inhibitors. This phase 2 clinical trial was conducted to evaluate the safety and efficacy of combining palliative SBRT with camrelizumab (an anti-PD1 monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jian-Xu, Su, Ting-Shi, Gong, Wen-Feng, Zhong, Jian-Hong, Yan, Liu-Ying, Zhang, Jie, Li, Li-Qing, He, Mei-Ling, Zhang, Rui-Jun, Du, You-Qin, Wang, Xiao-Ting, Liang, Shi-Xiong, Xiang, Bang-De
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525355/ https://www.ncbi.nlm.nih.gov/pubmed/36001228 http://dx.doi.org/10.1007/s12072-022-10396-7

Ejemplares similares

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
por: Su, Ting-Shi, et al.
Publicado: (2021)

Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma
por: Ji, Ren, et al.
Publicado: (2022)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
por: Jung, Da Hoon, et al.
Publicado: (2014)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma
por: Shi, Xiaonan, et al.
Publicado: (2023)

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
por: Li, Ting, et al.
Publicado: (2023)

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
por: Chiang, Chi-Leung, et al.
Publicado: (2019)

Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm
por: Su, Ting-Shi, et al.
Publicado: (2016)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
por: Li, Jian-Xu, et al.
Publicado: (2022)

Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma
por: Que, Jenny, et al.
Publicado: (2016)

Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol
por: Huang, Jun Tao, et al.
Publicado: (2023)

Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
por: Sun, Bo, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
por: Zhang, Rui-Jun, et al.
Publicado: (2023)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation
por: Fiorica, Francesco, et al.
Publicado: (2013)

Comparison of Combination Stereotactic Body Radiotherapy Plus High-Intensity Focused Ultrasound Ablation Versus Stereotactic Body Radiotherapy Alone for Massive Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2018)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
por: Lin, Zhenyu, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis
por: Pan, Yang-Xun, et al.
Publicado: (2020)

A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases
por: Fumagalli, Ingrid, et al.
Publicado: (2012)

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
por: Matsuo, Yukinori
Publicado: (2023)

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
por: Zhang, Tao, et al.
Publicado: (2016)

Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
por: Li, Jian-Xu, et al.
Publicado: (2022)

Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity
por: Liang, Ping, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
por: Stauder, Michael C., et al.
Publicado: (2010)

Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion
por: Su, Ting-Shi, et al.
Publicado: (2020)

Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis
por: Shui, Yongjie, et al.
Publicado: (2018)

Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study
por: Qing, Shui-Wang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bq6amhch5fr0ldp57989f6q1fa